Showing 672 news articles about New & experimental HIV treatments

Filters Content type: Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

People with limited treatment options

EMA panel recommends ibalizumab for multidrug-resistant HIV-1

Editor's pick
Medscape (requires free registration)
30 July 2019
Changing treatment

Biktarvy Suppresses HIV Well in Women and Those With Drug Resistance

Editor's pick
POZ
29 July 2019
New & experimental HIV treatments

2019 Pipeline Report

Editor's pick
TAG
23 July 2019
Pharmaceutical industry

GSK touts new Dovato switching data. Is it enough to shake Gilead's HIV lead?

Editor's pick
FiercePharma
11 July 2019
New & experimental HIV treatments

ViiV Healthcare receives EU marketing authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection

Editor's pick
ViiV press release
3 July 2019
New & experimental HIV treatments

1 Year After Approval: How Does D/C/F/TAF Measure Up?

Editor's pick
Contagion Live
1 July 2019
Vaginal rings & topical PrEP

Novel HIV-1 Inhibitor Shows Promise for Future Treatment of HIV in Women

Editor's pick
Infectious Disease Advisor
26 June 2019
Side effects

Major HIV drug calls for vigilance

Editor's pick
University of Duisberg-Essen
24 June 2019
HIV treatment for children & young people

Biktarvy Approved to Treat Pediatric Patients With HIV-1

Editor's pick
Monthly Prescribing Reference
20 June 2019
New & experimental HIV treatments

CytoDyn Announces Major Discovery for its Monotherapy Indication

Editor's pick
CytoDyn press release
20 June 2019
New & experimental HIV treatments

CytoDyn: Uncovering An Opportunity

Editor's pick
Seeking Alpha
12 June 2019
The search for a cure

Could gold be the key to making gene therapy for HIV, blood disorders more accessible?

Editor's pick
Phys.org
28 May 2019
New & experimental HIV treatments

CytoDyn Files Pivotal Trial Protocol for HIV Monotherapy with FDA

Editor's pick
CytoDyn press release
17 May 2019
Injectable & long-acting HIV treatment

NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens

Editor's pick
National Institute of Allergy and Infectious Diseases
9 May 2019
Injectable & long-acting HIV treatment

ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine

Editor's pick
ViiV press release
29 April 2019
New & experimental HIV treatments

ViiV Healthcare announces CHMP Positive Opinion for Dovato® (dolutegravir/lamivudine) as a once-daily, single-pill, two-drug regimen for the treatment of HIV infection

Editor's pick
ViiV press release
26 April 2019
Pharmaceutical industry

Gilead's first big TV push for triple combo Biktarvy showcases HIV diversity

Editor's pick
FiercePharma
18 April 2019
New & experimental HIV treatments

Novel Antibody May Suppress HIV for Up to Four Months

Editor's pick
NIAID
18 April 2019
Pharmaceutical industry

Dovato Is a Newly Approved Two-Drug HIV Regimen. Do Fewer Drugs Mean a Lower-Cost HIV Treatment?

Editor's pick
The Body
15 April 2019
Treatment simplification strategies

FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment

Editor's pick
Food & Drug Administration
9 April 2019
Side effects

HIV Drugs With Fewer Side Effects Need More FDA Support

Editor's pick
HivPlusMag.com
27 March 2019
New & experimental HIV treatments

Why 1 Top Analyst Thinks Gilead Sciences Will Soar More Than 25%

Editor's pick
Motley Fool
24 March 2019
New & experimental HIV treatments

Trogarzo’s Effects on Hard-to-Treat HIV Are Stable Over Two Years

Editor's pick
Poz
20 March 2019
New & experimental HIV treatments

HIV Drug Aiming to Free Patients From Daily Doses Nears Market

Editor's pick
Bloomberg
8 March 2019